Horama Company
Horama develops gene therapies for rare inherited ocular diseases.
Industry:
Gene Therapy
Technology:
Neurological Disorders
Funding Status:
Early Stage Venture
Investment Stage:
N/A
Estimated Revenue:
$1M to $10M
Investors Number:
9
Headquarters:
Paris, Ile-de-France, France
Employee Number:
11-50
Number Of Exists:
Series B
Investor Type:
Company
Total Funding:
â¬27.1M
Founded Date:
2014
Last Funding Type:
Series B